Lixte Biotechnology Holdings, Inc. (LIXT) financial statements (2020 and earlier)

Company profile

Business Address 248 ROUTE 25A
EAST SETAUKET, NY 11733
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2,5994,2731,3062002544475
Cash and cash equivalents2,5994,2731,3062002544475
Receivables14      
Prepaid expense 9     
Other undisclosed current assets59526223357349583
Total current assets:2,6724,3341,368433598539558
Noncurrent Assets
Prepaid expense 2     
Total noncurrent assets: 2     
TOTAL ASSETS:2,6724,3371,368433598539558
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:144195312160159123108
Interest and dividends payable    2  
Other undisclosed accounts payable and accrued liabilities144195312160157123108
Due to related parties     93 
Other undisclosed current liabilities9416615912758214
Total current liabilities:238211373219286273322
Noncurrent Liabilities
Total liabilities:238211373219286273322
Stockholders' equity
Stockholders' equity attributable to parent, including:2,4344,126995215312266236
Preferred stock3,5003,5003,5003,5001,750  
Common stock7765554
Additional paid in capital26,01625,26820,00517,41717,13015,97913,184
Accumulated deficit(27,089)(24,649)(22,515)(20,707)(18,572)(15,718) 
Other undisclosed stockholders' equity attributable to parent      (12,952)
Total stockholders' equity:2,4344,126995215312266236
TOTAL LIABILITIES AND EQUITY:2,6724,3371,368433598539558

Income statement (P&L) ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues
(Revenue, Net)
    200  
Cost of revenue
(Cost of Goods and Services Sold)
   (25)(53)(25) 
Gross profit:   (25)147(25) 
Operating expenses(2,490)(2,138)(1,810)(2,135)(2,846)(2,403)(1,375)
Other undisclosed operating income   255325 
Operating loss:(2,490)(2,138)(1,810)(2,135)(2,646)(2,403)(1,375)
Nonoperating income
(Investment Income, Nonoperating)
50510000
Net loss:(2,440)(2,133)(1,808)(2,135)(2,646)(2,403)(1,375)
Other undisclosed net loss attributable to parent    (206)(363) 
Net loss attributable to parent:(2,440)(2,133)(1,808)(2,135)(2,852)(2,766)(1,375)
Other undisclosed net loss available to common stockholders, basic    (2)  
Net loss available to common stockholders, diluted:(2,440)(2,133)(1,808)(2,135)(2,854)(2,766)(1,375)

Comprehensive Income ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(2,440)(2,133)(1,808)(2,135)(2,646)(2,403)(1,375)
Comprehensive loss, net of tax, attributable to parent:(2,440)(2,133)(1,808)(2,135)(2,646)(2,403)(1,375)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: